Brand name: Odefsey TM
Active ingredients: emtricitabine + rilpivirine + tenofovir alafenamide
What it is used for
ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents (12 years and older with body weight at least 35 kg) with plasma HIV-1 RNA <= 100,000 copies/mL at the start of therapy. The patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of ODEFSEY.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
F/R/TAF 200/25/25 mg tablets are grey, oval-shaped, film-coated tablets debossed with GSI on one side and 255 on the other side.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on April 1, 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient emtricitabine + rilpivirine + tenofovir alafenamide
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Download leaflet
For side effects, taking other medicines and more
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems